Literature DB >> 23430893

Gastrointestinal phenotype of fabry disease in a patient with pseudoobstruction syndrome.

Piotr Buda1, Anna Wieteska-Klimczak, Janusz Ksiazyk, Piotr Gietka, Anna Smorczewska-Kiljan, Maciej Pronicki, Barbara Czartoryska, Anna Tylki-Szymanska.   

Abstract

Fabry disease is a rare, X-linked inborn error of glycosphingolipid metabolism caused by a deficiency of the lysosomal enzyme α-galactosidase A. Progressive deposition of GL-3 starts early in life, presumably as early as in fetal life. Chronic burning or provoked attacks of excruciating pain in hands and feet in Fabry disease are common in most children as well as GI-symptoms.We describe a case of pediatric Fabry disease with gastrointestinal dysmotility symptoms as primary and most severe complaints. Colonic pseudoobstruction and necrosis developed by the age of 15 years. We hypothesize that this patient developed a gastrointestinal phenotype of pediatric Fabry disease that has not been described before.

Entities:  

Year:  2011        PMID: 23430893      PMCID: PMC3509874          DOI: 10.1007/8904_2011_63

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  14 in total

1.  Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide.

Authors:  C E Argoff; N W Barton; R O Brady; H A Ziessman
Journal:  Nucl Med Commun       Date:  1998-09       Impact factor: 1.690

Review 2.  Evaluation of peripheral and autonomic nerve function in Fabry disease.

Authors:  M J Hilz
Journal:  Acta Paediatr Suppl       Date:  2002

3.  High incidence of later-onset fabry disease revealed by newborn screening.

Authors:  Marco Spada; Severo Pagliardini; Makiko Yasuda; Turgut Tukel; Geetha Thiagarajan; Hitoshi Sakuraba; Alberto Ponzone; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2006-04-28       Impact factor: 11.025

4.  Gastrointestinal structure and function in Fabry's disease.

Authors:  K J Sheth; S L Werlin; M E Freeman; A E Hodach
Journal:  Am J Gastroenterol       Date:  1981-09       Impact factor: 10.864

5.  Small bowel perforation in Fabry's disease.

Authors:  A Bryan; R F Knauft; W A Burns
Journal:  Ann Intern Med       Date:  1977-03       Impact factor: 25.391

6.  Clinical benefit of enzyme replacement therapy in Fabry disease.

Authors:  F Breunig; F Weidemann; J Strotmann; A Knoll; C Wanner
Journal:  Kidney Int       Date:  2006-04       Impact factor: 10.612

7.  Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy.

Authors:  Bjoern Hoffmann; Martin Schwarz; Atul Mehta; Satish Keshav
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10-24       Impact factor: 11.382

8.  Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry's disease.

Authors:  B D O'Brien; T K Shnitka; R McDougall; K Walker; L Costopoulos; B Lentle; L Anholt; H Freeman; A B Thomson
Journal:  Gastroenterology       Date:  1982-05       Impact factor: 22.682

9.  Small bowel ischaemia in Fabry's disease.

Authors:  D L Jardine; M A Fitzpatrick; W D Troughton; A B Tie
Journal:  J Gastroenterol Hepatol       Date:  1994 Mar-Apr       Impact factor: 4.029

10.  Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.

Authors:  Stephen Waldek; Manesh R Patel; Maryam Banikazemi; Roberta Lemay; Philip Lee
Journal:  Genet Med       Date:  2009-11       Impact factor: 8.822

View more
  4 in total

Review 1.  Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis.

Authors:  Claire Zar-Kessler; Amel Karaa; Katherine Bustin Sims; Virginia Clarke; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2016-04-15       Impact factor: 4.409

Review 2.  Fabry disease - a multisystemic disease with gastrointestinal manifestations.

Authors:  Malte Lenders; Eva Brand
Journal:  Gut Microbes       Date:  2022 Jan-Dec

3.  Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.

Authors:  Frits A Wijburg; Bernard Bénichou; Daniel G Bichet; Lorne A Clarke; Gabriela Dostalova; Alejandro Fainboim; Andreas Fellgiebel; Cassiano Forcelini; Kristina An Haack; Robert J Hopkin; Michael Mauer; Behzad Najafian; C Ronald Scott; Suma P Shankar; Beth L Thurberg; Camilla Tøndel; Anna Tylki-Szymańska; Uma Ramaswami
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

Review 4.  Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.

Authors:  Fabio Caputo; Lisa Lungaro; Adriana Galdi; Eleonora Zoli; Fiorella Giancola; Giacomo Caio; Roberto De Giorgio; Giorgio Zoli
Journal:  Int J Environ Res Public Health       Date:  2021-03-23       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.